This drug has recently been touted as "The Holy Grail" for cancer treatment in patients suffering from cancer if they possess the BRCA mutation. Olaparib is a new type of cancer treatment which has produced highly promising results in preliminary drug trials.Olaparib (AZD-2281) is a PARP inhibitor anti-cancer drug intended primarily for patients with mutations in the genes BRCA1 or BRCA2. Phase I clinical trial results were encouraging especially in patients with BRCA deficient tumours includ...


Continue reading ...